Sepsia Therapeutics

Executive Summary

Sepsia Therapeutics, a Barcelona-based preclinical biotech, is developing novel broad-spectrum drug and cell therapies against sepsis—a life-threatening condition caused by the host's dysregulated response to infection. The company's platform leverages host scavenger-like receptors on lymphocytes to neutralize conserved inflammation-promoting structures on bacteria and fungi. This approach targets both microbial components and the host inflammatory response, potentially offering advantages over current treatments that focus solely on pathogen elimination. Founded in 2019, Sepsia is advancing its lead candidates through preclinical studies, aiming to address the high unmet need in sepsis, which affects millions globally with limited therapeutic options. The company's innovative mechanism and early-stage progress position it as a promising player in the sepsis therapy landscape, though it remains pre-revenue and requires significant clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Presentation of preclinical proof-of-concept data70% success
• Q3 2026Series A financing round60% success
• Q4 2026Research collaboration or licensing deal40% success